Skip to main content

Table 1 Associations of the trajectory groups with CVDs and all-cause mortalitya

From: Moderate physical activity may not decrease the risk of cardiovascular disease in persistently overweight and obesity adults

 

Numberb

Rate (‰)c

Model 1e

P

Model 2f

P

Model 3g

P

HR (95% CI)

HR (95% CI)

HR (95% CI)

CVDsd

        

 Persistent NW with MPA (reference)

1208

3.81

–

–

–

–

–

–

 Rising to OW in NW status with MPA

275

3.20

0.83 (0.73–0.94)

0.0042

0.94 (0.82–1.07)

0.3424

0.93 (0.81–1.06)

0.2701

 Persistent OW with MPA

1836

5.33

1.40 (1.30–1.50)

 < 0.0001

1.37 (1.27–1.47)

 < 0.0001

1.31 (1.22–1.41)

 < 0.0001

 Decline to NW in OW status with MPA

338

4.17

1.08 (0.96–1.22)

0.1977

1.00 (0.88–1.13)

0.9688

0.96 (0.85–1.06)

0.5168

 Decline to OW in obesity status with MPA

252

5.00

1.30 (1.13–1.49)

0.0002

1.24 (1.08–1.42)

0.0022

1.15 (1.00–1.32)

0.0494

 Persistent obesity with MPA

843

6.23

1.64 (1.50–1.79)

 < 0.0001

1.69 (1.55–1.85)

 < 0.0001

1.55 (1.41–1.69)

 < 0.0001

MI

        

 Persistent NW with MPA (reference)

217

3.81

–

–

–

–

–

–

 Rising to OW in NW status with MPA

36

3.20

0.61 (0.43–0.86)

0.0055

0.68 (0.48–0.98)

0.0366

0.67 (0.47–0.96)

0.0299

 Persistent OW with MPA

323

5.33

1.36 (1.15–1.62)

0.0005

1.33 (1.12–1.58)

0.0012

1.27 (1.07–1.501)

0.0076

 Decline to NW in OW status with MPA

51

4.17

0.91 (0.67–1.24)

0.5447

0.84 (0.62–1.14)

0.2594

0.79 (0.58–1.08)

0.1412

 Decline to OW in obesity status with MPA

42

5.00

1.20 (0.86–1.67)

0.2764

1.15 (0.82–1.60)

0.4151

1.06 (0.76–1.47)

0.7465

 Persistent obesity with MPA

156

6.23

1.67 (1.36–2.05)

 < 0.0001

1.71 (1.39–2.11)

 < 0.0001

1.53 (1.24–1.89)

 < 0.0001

Stroke

        

 Persistent NW with MPA (reference)

1008

3.81

–

–

–

–

–

–

 Rising to OW in NW status with MPA

240

3.20

0.86 (0.75–1.00)

0.0420

0.99 (0.86–1.13)

0.8327

0.98 (0.85–1.13)

0.7419

 Persistent OW with MPA

1539

5.33

1.40 (1.29–1.52)

 < 0.0001

1.37 (1.27–1.49)

 < 0.0001

1.31 (1.21–1.42)

 < 0.0001

 Decline to NW in OW status with MPA

291

4.17

1.12 (0.98–1.27)

0.0920

1.03 (0.91–1.18)

0.6309

1.00 (0.88–1.14)

0.9831

 Decline to OW in obesity status with MPA

214

5.00

1.32 (1.14–1.53)

0.0002

1.26 (1.09–1.46)

0.0022

1.17 (1.01–1.36)

0.0402

 Persistent obesity with MPA

701

6.23

1.63 (1.48–1.80)

 < 0.0001

1.68 (1.53–1.85)

 < 0.0001

1.54 (1.40–1.70)

 < 0.0001

All-cause mortality

        

 Persistent NW with MPA (reference)

3072

9.35

–

–

–

–

–

–

 Rising to OW with MPA in NW status with APA

482

5.19

0.55 (0.50–0.60)

 < 0.0001

0.73 (0.66–0.80)

 < 0.0001

0.72 (0.65–0.79)

 < 0.0001

 Persistent OW with MPA

3198

8.52

0.91 (0.86–0.95)

0.0001

0.95 (0.90–1.00)

0.0335

0.92 (0.87–0.97)

0.0008

 Decline to NW in OW status with MPA

603

7.48

0.79 (0.73–0.87)

 < 0.0001

0.75 (0.68–0.81)

 < 0.0001

0.73 (0.67–0.80)

 < 0.0001

 Persistent obesity with MPA

1499

9.02

0.96 (0.90–1.02)

0.2118

1.06 (0.99–1.13)

0.0647

1.00 (0.94–1.06)

0.9347

  1. APA active physical activity, CI confidence interval, CRP c-reaction protein, CVD cardiovascular disease, HR hazard ratio, MI myocardial infarction, MPA moderate physical activity, NW normal-weight, OW overweight
  2. aMultivariate cox regression analysis was used to evaluate the associations of CVDs and all-cause mortality risk with trajectory groups, adjusting for potential confounding factors
  3. bNumber represented the number of events
  4. cPer 1,000 person-years
  5. dCVDs included MI and stroke (cerebral infarction, cerebral hemorrhages, and subarachnoid hemorrhage)
  6. eModel 1 was a crude model without adjusted covariates
  7. fModel 2 was adjusted for age, sex, type of work, seat time, and walking instead of the elevators
  8. gModel 3 was further adjusted for educational level, smoking status, drinking status, family per-member monthly income, salt intake, drinking tea status, CRP, and history of diseases (hypertension, diabetes, and hyperlipidemia)
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us